Physician-Led Weight Loss Using Semaglutide and Tirzepatide — Medically Supervised, Evidence-Based Results
Initial visit + labs: $250
Who It's For
Medical weight loss may be appropriate if you:
Have struggled to lose weight or maintain weight loss through diet and exercise alone
Carry excess weight that is affecting your energy, joints, metabolic health, or quality of life
Have been told you are pre-diabetic, insulin resistant, or have metabolic syndrome
Want a medically supervised approach with accountability and ongoing support
How It Works
Initial visit + labs$250
Tirzepatide vial$530 · lasts 1–6 months depending on dose
Semaglutide vial$399 · lasts 1–6 months depending on dose
Follow-up visit + labs (every 6 months)$250
Medication costs depend on dose and duration. Discussed in detail at your initial consultation.
GLP-1 receptor agonists mimic a naturally occurring gut hormone that regulates appetite, insulin secretion, gastric emptying, and fat metabolism. Your program includes comprehensive metabolic labs and provider evaluation, a personalized GLP-1 protocol — semaglutide or tirzepatide based on your profile — dose titration over time, ongoing provider check-ins and lab monitoring, and nutritional and lifestyle guidance.
What to Expect
Most patients begin to notice reduced appetite and early weight changes within the first 2–4 weeks. Meaningful weight loss typically accumulates over 3–6 months as the dose is optimized. This is a medically supervised program with accountability built in.
Results
Clinical trials and real-world experience show:
Average weight loss of up to 20% of body weight with tirzepatide over 12–18 months
Average weight loss of up to 15% of body weight with semaglutide over 12–18 months
Significant improvements in blood sugar, blood pressure, and lipid profiles
Reduced hunger and food cravings
Improved energy and mobility as weight decreases
Safety & Side Effects
GLP-1 therapies have been extensively studied and are FDA-approved for weight management. Common considerations include nausea (most common side effect, typically mild), gastrointestinal symptoms, and injection site reactions. Patients with personal or family history of medullary thyroid cancer or MEN2 are not candidates.
Frequently Asked Questions
Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist. Tirzepatide (Mounjaro, Zepbound) works on both GLP-1 and GIP receptors — a dual mechanism that tends to produce greater weight loss.
Weight regain is common after stopping GLP-1 therapy, as these medications address the hormonal drivers of appetite. We discuss long-term planning and sustainability at your consultation.
Your initial visit includes labs and a full evaluation. Follow-up visits and labs are done every 6 months, with provider access in between for questions or dose adjustments.
Side Effects
Nausea: Most common — reduced by small meals, avoiding high-fat foods.
Constipation: Increase fluids and fiber.
Reflux / heartburn: Smaller meals; avoid lying down after eating.
Hair thinning: Usually related to rapid weight loss; temporary.
⚠ Contact Us Immediately: Severe persistent abdominal pain radiating to back (pancreatitis — ER immediately) · Can't keep fluids down >24 hrs · Severe right-sided upper abdominal pain (gallstones)
Timeline
Timeframe
What to Expect
Weeks 1–2
Appetite reduction; feeling full on less food
Weeks 2–4
Early weight changes (2–5 lbs)
Months 2–3
1–2 lbs/week as dose optimizes
Months 6–18
Full potential: semaglutide ~15%, tirzepatide ~20% body weight
Injection Instructions
Once weekly, same day each week. Missed dose: if >2 days until next dose, take as soon as remembered. If <2 days, skip. Never double dose.